Abstract
Amiodarone was introduced as an antiarrhythmic compound in the early 1970s and was approved in the U.S. for the treatment of refractory ventricular arrhythmias in late 1984. Since that time the drug has become the most widely studied antiarrhythmic compound with expanding potential indications, including maintaining stability of sinus rhythm, secondary prevention in the survivors of myocardial infarction, and prolongation of survival in certain subsets of patients with congestive heart failure. Intravenous amiodarone was introduced in the U.S. in 1995 for the control of recurrent destabilizing ventricular tachycardia or ventricular fibrillation resistant to conventional therapy. The level of comfort in its use has risen considerably in the recent past. This has stemmed from the reasonably decisive evidence that class I agents increase mortality in patients with structural heart disease. In contrast, amiodarone either reduces mortality or its effect is neutral; this is consistent with its low to negligible proarrhyfhmic actions. The drug does not aggravate heart failure and it may even increase left ventricular ejection fraction and improve exercise capacity. Above all, it is becoming increasingly evident from wider experience and from controlled clinical trials that the side‐effect profile of the drug is not as compelling an issue as it appeared to be when first used in much higher doses. Therefore, the overall objective of amiodarone therapy is to use the lowest dose that produces a defined therapeutic end point without causing serious side effects. Careful clinical surveillance in conjunction with monitoring of certain laboratory parameters and indices of efficacy at regular intervals permits the drug to be used effectively in a large number of patients who fail to respond to, or are intolerant of other antiarrhythmic compounds. Many experienced clinicians have begun to consider the use of amiodarone as first‐line therapy in certain disorders of rhythm, especially in patients with severely compromised ventricular function.
Keywords: class III antiarrhythmic drugs, ventricular tachycardia and fibrillation, sptalol, atrial fibrillation, heart failure, myocardial infarction, proarrhythmia, monitoring amiodarone therapy
Full Text
The Full Text of this article is available as a PDF (1.2 MB).
References
- 1. Singh B: Expanding indications for the use of class III agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol 1995; 6: 887–900 [DOI] [PubMed] [Google Scholar]
- 2. Nademanee K: The amiodarone odyssey. J Am Coll Cardiol 1992; 20: 1063–1065 [DOI] [PubMed] [Google Scholar]
- 3. Singh BN, Venkatesh N, Nademanee K, Josephson M, Kannan R: The historical development, cellular electrophysiology and pharmacology of amiodarone. Prog Cardiovasc Dis 1989; 31: 249–280 [DOI] [PubMed] [Google Scholar]
- 4. Nademanee K, Singh BN, Hendrickson J, Intrarachet V, Lopez B, Feld G, Cannom D, Weiss JN: Amiodarone in refractory life‐threatening ventricular arrhythmias. Ann Intern Med 1983; 98: 577–584 [DOI] [PubMed] [Google Scholar]
- 5. Herre JM, Sauve MJ, Griffin JC, Helmy L, Langberg JJ, Goldberg H, Scheinman MM: Longterm results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989; 13: 442–449 [DOI] [PubMed] [Google Scholar]
- 6. Weinberg BA, Miles WM, Klein LS, Zipes DP: Five year follow‐up of 589 patients treated with amiodarone. Am Heart J 1993; 125: 109–120 [DOI] [PubMed] [Google Scholar]
- 7. The CASCADE Investigators : The Cascade study—randomized anti‐arrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol 1993; 72: 280–287 [DOI] [PubMed] [Google Scholar]
- 8. Singh BN: Implantable cardioverter‐defibrillators: Not the ultimate gold standard for gauging therapy of ventricular tachycardia and fibrillation? Am J Cardiol 1994; 73: 1211–1213 [DOI] [PubMed] [Google Scholar]
- 9. Zipes DP: Implantable cardioverter‐defibrillator: Life saver or a device looking for a disease? Circulation 1994; 91: 2115–2117 [DOI] [PubMed] [Google Scholar]
- 10. Kim SG: Evaluation of the management of malignant ventricular tachyarrhythmias: The roles of drug therapy and implantable defibrillators. Am Heart J 1995; 130: 1144–1150 [DOI] [PubMed] [Google Scholar]
- 11. Siebels J, Cappato R, Ruppel R, Schneider M, Kuck KH: Preliminary results of the cardiac arrest study Hamburg (CASH). Am J Cardiol 1993; 72: 109F–113F [DOI] [PubMed] [Google Scholar]
- 12. Connolly SJ, Gent M, Roberts RS, Cairns JA, on behalf of the CIDS Collaborators : Canadian implantable defibrillator study (CIDS): Study design and organization. Am J Cardiol 1993; 72: 103F–108F. [DOI] [PubMed] [Google Scholar]
- 13. Scheinman MM, Levine JH, Cannom DS, Kopelman FT, Chilson DA, Platia EV, Wilber DJ, Kowey PR, for the Intravenous Amiodarone Multicenter Investigators Group : Dose‐ranging study of intravenous amiodarone in patients with life‐threatening ventricular tachyarrhythmias. Circulation 1995; 92: 3264–3272 [DOI] [PubMed] [Google Scholar]
- 14. Kowey PR, Levine JH, Pacifico A, Lindsay BD, Plumb VJ, Janosik DJ, Kopelman HA, Scheinman MM, for the Intravenous Amiodarone Multicenter Investigators Group : Randomized, double‐blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia and fibrillation. Circulation 1995; 92: 3255–3263 [DOI] [PubMed] [Google Scholar]
- 15. Singh BN: Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Am J Cardiol 1996; 78 (suppl 4A): 41–53 [DOI] [PubMed] [Google Scholar]
- 16. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis DL, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EE, Weaver D: ACC/AHA guidelines for management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28: 1328–1428 [DOI] [PubMed] [Google Scholar]
- 17. Nademanee K, Singh BN, Stevenson WG, Weiss JN: Amiodarone and the post‐MI patient. Circulation 1993; 88: 764–774 [DOI] [PubMed] [Google Scholar]
- 18. Cairns JA, Connolly SJ, Gent M, Roberts R: Post‐myocardial infarction mortality in patients with premature depolarizations: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. J Am Coll Cardiol 1991; 84: 550–557 [DOI] [PubMed] [Google Scholar]
- 19. Cairns JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators : Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997; 349: 675–682 [DOI] [PubMed] [Google Scholar]
- 20. Camm AJ, Julian D, Janse G, Munoz A, Schwartz PJ, Simon P: The European Myocardial Infarct Amiodarone Trial (EMIAT). Am J Cardiol 1993; 72: 95F–98F [DOI] [PubMed] [Google Scholar]
- 21. Julian D, Camm AJ, Franglin G, Janse MJ, Munoz A, Schwartz PJ, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators : EMIAT. Lancet 1997; 349: 667–674 [DOI] [PubMed] [Google Scholar]
- 22. Singh SN, Gross Fisher S, Fletcher RD, Singh BN, Deedwania PC, Massie BM, Lewis D, and the CHF STAT Investigators : Amiodarone in patients with congestive heart failure with asymptomatic ventricular arrhythmias. N Engl J Med 1995; 33: 77–82 [DOI] [PubMed] [Google Scholar]
- 23. Massie BM, Fisher SG, Deedwania PC, Singh BN, Fletcher RD, Singh SN for the CHF STAT Investigators : Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 1996; 93: 21: 2128–2134 [DOI] [PubMed] [Google Scholar]
- 24. Doval HC, Nul DR, Vancelli HO, Elizari M: Randomized trial of low‐dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493–498 [DOI] [PubMed] [Google Scholar]
- 25. Olsson B, Brorson L, Varnauskas E: Class III antiarrhythmic action in man. Observations from monophasic action potential recordings and amiodarone treatment. Br Heart J 1973; 35: 1255–1259 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Middlekauff HR, Wiener I, Saxon LA, Stevenson WG: Low‐dose amiodarone for atrial fibrillation. Time for a prospective study? Ann Intern Med 1992; 116: 1017–1020 [DOI] [PubMed] [Google Scholar]
- 27. Chun S, Sager FT, Stevenson WG, Nademanee K, Middlekauff HR, Singh B: Amiodarone is highly effective in maintaining NSR in refractory atrial fibrillation/flutter. Am J Cardiol 1995; 76: 47–53 [DOI] [PubMed] [Google Scholar]
- 28. Beghi E, Monticelli ML, Bono A, Bogliun G: Antiarrhythmic drugs and polyneuropathy. J Neurol Neurosurg Psychial 1994; 57: 340–343 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Ceremuzynski L, Kleczar E, Krezminska‐Pakula M, Kuch J, Nartowicz R, Smielak‐Korombel J, Dydusyaski I, Maciejewicz J, Zaleska T, Lazarczyk‐Kedizia E, Motyka J, Paczkowska B, Sczanjecka O, Yusuf S: Effect of antiarrhythmic therapy on mortality after myocardial infarction. J Am Coll Cardiol 1992; 20: 1056–1062 [DOI] [PubMed] [Google Scholar]
- 30. Holnloser S, Klingenheben T, Singh BN: Amiodarone‐associated proarrhythmic effects: A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994; 121: 529–535 [DOI] [PubMed] [Google Scholar]
- 31. Nasir N, Swarna US, Boehene KA, Doyle TK, Pacifico A: Therapy of sustained ventricular arrhythmias with amiodarone: Prediction of efficacy with serial electrophysiologic testing. J Cardiovasc Pharmacol Ther 1996; 1: 123–132 [DOI] [PubMed] [Google Scholar]